SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (32829)11/5/2009 10:32:10 PM
From: Biomaven1 Recommendation  Respond to of 52153
 
It's my understanding that under the old deal MEDI had to pay for all production of the antibody. Under the new deal, its all on MITI's dime. (This has nothing to do with whether the manufacturing is or contracted out). So the fee MITI is paying to undo their deal is higher than it at first looks.

Sounds to me like MEDI's internal CD19 program played a part here. It's all certainly cleaner this way and the ultimate upside has to be better.

Peter


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News